Arcutis Biotherapeutics (NASDAQ:ARQT) Reaches New 12-Month High – Should You Buy?

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT)’s stock price hit a new 52-week high during mid-day trading on Wednesday. The company traded as high as $33.52 and last traded at $33.4610, with a volume of 638,876 shares changing hands. The stock had previously closed at $32.00.

Trending Headlines about Arcutis Biotherapeutics

Here are the key news stories impacting Arcutis Biotherapeutics this week:

• Positive Sentiment: Arcutis raised its 2026 sales guidance, a sign of improved commercial expectations. However, investors may be weighing whether the stronger outlook is already reflected in the stock. Article: Arcutis Biotherapeutics Raised 2026 Sales Guidance
• Positive Sentiment: The company began enrolling participants in a Phase 3 study of ZORYVE cream 0.3% for moderate-to-severe atopic dermatitis. Success could expand the medicine’s potential market, though this remains a clinical-development catalyst. Article: Arcutis Begins Enrolling Phase 3 ZORYVE Study
• Neutral Sentiment: Arcutis granted stock options and restricted stock units to six new employees. The awards create some share dilution, but are routine hiring-related inducements and are not a major business update. Article: Arcutis Reports Inducement Grants
• Negative Sentiment: Third-quarter EPS was $0.06, below analyst expectations of roughly $0.17–$0.18. Revenue of $143.92 million narrowly topped forecasts, but the earnings miss appears to be the more immediate sentiment driver. Article: Arcutis Falls After Q3 Earnings Miss
• Negative Sentiment: HC Wainwright cut its EPS estimates for the first three quarters of 2027, including reducing its Q2 forecast from $0.19 to $0.14. The lowered projections add to concerns following the quarterly earnings shortfall.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on the stock. Needham & Company LLC set a $40.00 price objective on shares of Arcutis Biotherapeutics in a report on Thursday. Morgan Stanley raised their price target on Arcutis Biotherapeutics from $34.00 to $38.00 and gave the stock an “overweight” rating in a research report on Thursday, August 6th. Jefferies Financial Group reissued a “buy” rating and issued a $39.00 price objective on shares of Arcutis Biotherapeutics in a research report on Thursday, October 8th. Cantor Fitzgerald started coverage on Arcutis Biotherapeutics in a research note on Thursday, October 15th. They set an “overweight” rating and a $48.00 price objective for the company. Finally, TD Cowen lifted their price target on Arcutis Biotherapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a report on Thursday. Eight analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Arcutis Biotherapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $39.75.

Arcutis Biotherapeutics Stock Performance

The company has a market capitalization of $3.21 billion, a price-to-earnings ratio of 121.67 and a beta of 1.66. The company has a debt-to-equity ratio of 0.46, a current ratio of 2.92 and a quick ratio of 2.67. The stock has a 50 day moving average price of $27.15 and a two-hundred day moving average price of $25.37.

Arcutis Biotherapeutics (NASDAQ:ARQT) last announced its quarterly earnings results on Wednesday, November 4th. The company reported $0.06 earnings per share for the quarter, missing analysts’ consensus estimates of $0.18 by ($0.12). The firm had revenue of $143.92 million for the quarter, compared to the consensus estimate of $142.59 million. Arcutis Biotherapeutics had a return on equity of 14.96% and a net margin of 5.88%. On average, analysts predict that Arcutis Biotherapeutics, Inc. will post 0.43 EPS for the current fiscal year.

Insiders Place Their Bets

In other Arcutis Biotherapeutics news, EVP Masaru Matsuda sold 40,000 shares of the company’s stock in a transaction dated Wednesday, November 4th. The stock was sold at an average price of $34.32, for a total value of $1,372,800.00. Following the completion of the transaction, the executive vice president owned 111,289 shares of the company’s stock, valued at $3,819,438.48. This represents a 26.44% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Todd Watanabe sold 4,377 shares of the company’s stock in a transaction dated Monday, November 2nd. The shares were sold at an average price of $31.86, for a total value of $139,451.22. Following the completion of the sale, the insider owned 712,826 shares in the company, valued at $22,710,636.36. This trade represents a 0.61% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 123,932 shares of company stock worth $3,553,077 over the last three months. 9.40% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the stock. Pinnacle Wealth Planning Services Inc. bought a new stake in shares of Arcutis Biotherapeutics in the 3rd quarter worth $36,000. Allworth Financial LP lifted its stake in Arcutis Biotherapeutics by 158.2% during the 3rd quarter. Allworth Financial LP now owns 2,089 shares of the company’s stock valued at $55,000 after acquiring an additional 1,280 shares during the period. Nykredit A S bought a new stake in shares of Arcutis Biotherapeutics in the second quarter worth approximately $63,000. Integrated Wealth Concepts LLC purchased a new position in shares of Arcutis Biotherapeutics during the second quarter valued at approximately $84,000. Finally, Sterling Capital Management LLC lifted its position in Arcutis Biotherapeutics by 839.3% during the third quarter. Sterling Capital Management LLC now owns 3,776 shares of the company’s stock valued at $100,000 after purchasing an additional 3,374 shares during the period.

About Arcutis Biotherapeutics

Arcutis Biotherapeutics, Inc is a commercial-stage biopharmaceutical company focused on developing and delivering treatments for dermatologic conditions. The company’s portfolio is centered on therapies designed to address inflammatory skin diseases, with an emphasis on nonsteroidal topical medicines that may help patients manage chronic conditions.

Arcutis’s lead product is ZORYVE (roflumilast), a topical phosphodiesterase-4 inhibitor. ZORYVE has received U.S. Food and Drug Administration approvals for multiple dermatological uses, including plaque psoriasis, seborrheic dermatitis and atopic dermatitis, in different cream and foam formulations.